China-based Precision Biotech has announced a strategic partnership with compatriot firm T&L Biotechnology Co., Ltd. to collaborate on the development and supply of cell sorting magnetic bead reagents. This alliance aims to enhance the research and development (R&D) and commercialization efforts in the field of cell and gene therapies (CGT), although no financial details have been disclosed.
Boosting R&D and Commercialization in CGT
The partnership between Precision Biotech and T&L Biotechnology is set to bolster the R&D and commercialization of cell and gene therapies, a rapidly growing sector in the biopharmaceutical industry. By working closely together, the two companies aim to leverage their respective expertise to advance the development of innovative therapies.
Precision Biotech’s CAR-T Therapy and Regulatory Status
Precision Biotech, a specialist in CGT, is known for its CD19-targeted chimeric antigen receptor (CAR-) T therapy, pCAR-19B. This therapy is currently awaiting regulatory decisions in China for the treatment of childhood leukemia and has been granted priority review status. The therapy’s potential approval highlights the company’s commitment to bringing cutting-edge treatments to market.-Fineline Info & Tech
